Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Brookview Hills Research

Neither a doctor nor a teaching hospital

Research payments

$2,141,753

565 payments

Through program year 2025, Brookview Hills Research is reported as receiving $2,141,753 in research payments, across 565 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $789,293 27
2024 Research $387,843 17
2023 Research $120,456 157
2022 Research $170,003 73
2021 Research $234,609 108
2020 Research $280,631 126
2019 Research $158,917 57

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $989,790 41 payments
  2. Boehringer Ingelheim Pharma GmbH & Co.KG $334,334 12 payments
  3. Boehringer Ingelheim International GmbH $264,248 21 payments
  4. Novo Nordisk AS $257,796 408 payments
  5. GlaxoSmithKline, LLC. $207,708 52 payments
  6. Alexion Pharmaceuticals, Inc. $21,390 3 payments
  7. AstraZeneca UK Limited $21,308 4 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $19,742 2 payments
  9. Retrophin, Inc. $13,361 13 payments
  10. Sanofi US Services Inc. $5,266 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease $532,408 17 payments
  2. A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $426,338 2 payments
  3. Nn9535-4321 $257,796 408 payments
  4. A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease $232,129 4 payments
  5. A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $207,708 52 payments
  6. Cardiovascular Renal and Metabolism Lokelma Hyperkalemia $75,007 7 payments
  7. a phase I and IIa randomized,double blind,placebo controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end stage kidney disease receiving hemodialysis through a central venous catheter $61,845 1 payment
  8. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $51,362 8 payments
  9. Empa Kidney $46,822 2 payments
  10. TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal $42,072 7 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $13,361 13 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record